BioNexus Gene Lab Corp Rises 64.79% on Technical Momentum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Dec 25
Source: 8-K
BioNexus Gene Lab Corp. has seen a significant price increase of 64.79% in pre-market trading, crossing above the 5-day SMA.
This surge in stock price indicates strong technical momentum, reflecting positive investor sentiment.
The broader market is also showing gains, with the Nasdaq-100 up 0.38% and the S&P 500 up 0.24%, contributing to the favorable trading environment.
Analyst Views on BGLC
About BGLC
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
